1. Home
  2. CVKD vs NUWE Comparison

CVKD vs NUWE Comparison

Compare CVKD & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

N/A

Current Price

$1.71

Market Cap

3.4M

Sector

Health Care

ML Signal

N/A

Logo Nuwellis Inc.

NUWE

Nuwellis Inc.

N/A

Current Price

$3.77

Market Cap

3.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CVKD
NUWE
Founded
2022
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
3.2M
IPO Year
2022
2012

Fundamental Metrics

Financial Performance
Metric
CVKD
NUWE
Price
$1.71
$3.77
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $14.00
N/A
AVG Volume (30 Days)
103.3K
★ 1.4M
Earning Date
11-16-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 23.94
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $8,270,000.00
Revenue This Year
N/A
$19.32
Revenue Next Year
N/A
$12.01
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.82
$0.28
52 Week High
$12.50
$222.30

Technical Indicators

Market Signals
Indicator
CVKD
NUWE
Relative Strength Index (RSI) 66.44 40.20
Support Level $0.88 $0.28
Resistance Level $2.23 $5.74
Average True Range (ATR) 0.21 0.51
MACD 0.07 0.02
Stochastic Oscillator 78.44 0.86

Price Performance

Historical Comparison
CVKD
NUWE

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

About NUWE Nuwellis Inc.

Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

Share on Social Networks: